Diagnostic tests and prognostic indicators

Iterative Decomposition of Water and Fat with Echo Asymmetry and Least-Squares Estimation (IDEAL) Magnetic Resonance Imaging as a Biomarker for Symptomatic Multiple Myeloma. Takasu M et al. PLoS One. 2015 Feb 23;10(2):e0116842. doi: 10.1371/journal.pone.0116842. Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Vij R et al. Leuk Lymphoma. 2015 Feb 20:1-12. [Epub ahead…

Diagnosing and Monitoring Myeloma, Journal, Library

Emerging treatments

Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Mikhael JR et al. Br J Haematol. 2015 Feb 13. doi: 10.1111/bjh.13296. [Epub ahead of print]. Everolimus (RAD001) Activity in Relapsed and/or Refractory Multiple Myeloma: A Phase I Study. Guenther A et al. Haematologica. 2015 Feb 14. pii: haematol.2014.116269. [Epub ahead of print]. Phase I/II Study of the Combination…

Journal, Library

Biology and genetics

Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells. Anastasiadou E et al. Int J Cancer. 2015 Feb 20. doi: 10.1002/ijc.29489. [Epub ahead of print]. BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance. Dai Y et al. Autophagy. 2015 Feb 20:0. [Epub ahead of print]. Hyaluronan synthase 1: a mysterious enzyme with unexpected functions. Siiskonen H et…

Journal, Library, Management of Myeloma

Supportive care

OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Holtick U et al. Eur J Haematol. 2015 Feb 23. doi: 10.1111/ejh.12541. [Epub ahead of print]. Use of allogeneic platelet gel in the management of chemotherapy extravasation injuries: a case report. Di Costanzo G et al. Onco…

Journal, Library, Myeloma Prognosis & Outcomes

General

The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence. Hostenkamp G et al. Soc Sci Med. 2015 Feb 7;130C:162-171. doi: 10.1016/j.socscimed.2015.02.003. [Epub ahead of print]. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. Ashjian E et al. J Oncol Pharm Pract. 2015 Feb 17. pii: 1078155215572036. [Epub ahead of print]. Advance…

Journal, Library

Complications of myeloma and its treatments

Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment. Wang L et al. Clin J Oncol Nurs. 2015 Feb 1;19(1):E4-7. doi: 10.1188/15.CJON.E4-E7. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Peng L et al. Support Care Cancer. 2015 Feb 13. [Epub ahead of print]. Renal insufficiency retains adverse prognostic implications despite renal function improvement following…

Journal, Library, Management of complications & side effects